RFVIIIFc: Phase I/IIa data

In an open-label, crossover, dose-escalation Phase I/IIa trial in 16 treatment-experienced patients with severe hemophilia A, 25-65 IU/kg doses of IV rFVIIIFc were well tolerated and demonstrated a prolonged half-life across all doses compared to that of Advate octocog alfa. There were no signs of injection site reactions or anti-rFVIIIFc antibodies, and no drug-related serious adverse events were reported. Data were presented at the World Federation of Hemophilia Congress in Buenos Aires. ...